Rigel Pharmaceuticals RIGL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's cash & equivalents?
- Rigel Pharmaceuticals (RIGL) reported cash & equivalents of $24.47M in Q1 2026.
- How has Rigel Pharmaceuticals's cash & equivalents changed year-over-year?
- Rigel Pharmaceuticals's cash & equivalents decreased by 46.6% year-over-year, from $45.79M to $24.47M.
- What is the long-term trend for Rigel Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's cash & equivalents has grown at a 6.0% compound annual growth rate (CAGR), from $30.37M to $40.64M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.